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autoimmune manifestations. Kidney involvement has been rarely reported in MDS patients. We report on
the spectrum of kidney pathological findings in MDS patients.
Methods: We retrospectively identified MDS patients who had undergone a kidney biopsy between 2001
and 2019 in nine Swiss and French nephrology centres.
Results: Nineteen patients (median age 74 years [63-83]) were included. At the time of kidney biopsy,
eleven (58%) patients had extra-renal auto-immune manifestations and sixteen (84%) presented with
acute kidney injury. Median serum creatinine at diagnosis was 2.8 mg/dL [0.6-8.3] and median uri-
nary protein to creatinine ratio was 1.2 g/g [0.2-11]. Acute tubulo-interstitial nephritis (TIN) was
present in seven (37%) patients. Immunofluorescence study in one patient with acute TIN disclosed
intense IgG deposits along the tubular basement membrane and Bowman’s capsule. Other kidney
pathological features included ANCA-negative pauci-immune necrotizing and crescentic glomerulo-
nephritis (n ¼ 3), membranous nephropathy (n ¼ 2), IgA nephropathy (n ¼ 1), IgA vasculitis (n ¼ 1),
immunoglobulin-associated membrano-proliferative glomerulonephritis type I (n¼1), crescentic C3
glomerulopathy (n ¼ 1), fibrillary glomerulonephritis (n ¼ 1) and minimal change disease (n ¼ 1).
Eleven (58%) patients received immunosuppressive treatments, among whom one developed a se-
vere infectious complication. After a median follow-up of 7 month [1-96], nine (47%) patients had
chronic kidney disease stage 3 (n ¼ 6) or 4 (n ¼ 3) and five (26%) progressed to end-stage kidney
disease. Three patients died.
Conclusions: MDS are associated to several autoimmune kidney manifestations, predominantly acute TIN.
MDS are to be listed among the potential causes of autoimmune TIN.
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MDS are a heterogeneous group of acquired clonal
disorders defined by ineffective haematopoiesis with
dysplasia in one or several hematopoietic cell lineages
leading to cytopenias.1 MDS carry a high morbidity
related mainly to infections, bleeding and leukemic
transformation. In contrast, MPN, which include
polycythemia vera, essential thrombocythemia, chronicKidney International Reports (2021) 6, 746–754
N Schwotzer et al.: Myelodysplastic Syndromes and the Kidney CLINICAL RESEARCHmyeloid leukemia and primary myelofibrosis, are
characterized by predominant peripheral blood cell
proliferation.1,2 Chronic myelomonocytic leukaemia,
initially considered to be part of the spectrum of MDS,
is now placed into a separate category with both
myeloproliferative and myelodysplastic features.
MDS are also characterized by a unique high preva-
lence of associated autoimmune manifestations reported
in 10-20% of patients.3-6 These autoimmune manifesta-
tions encompass systemic vasculitis, connective tissue
diseases (including incomplete or unclassified forms),
immune-mediated haematological abnormalities, isolated
autoimmune diseases and asymptomatic serological
autoimmune features.7 Conversely, a history of an auto-
immune disease has been associated with an increased
risk of developing MDS.8,9
Kidney is a major target of autoimmunity. However,
kidney involvement has been rarely reported in pa-
tients with MDS, mostly in case reports 10,11 and kid-
ney pathological data are particularly scarce in this
setting. We aimed to describe the spectrum of kidney
pathological findings in patients with MDS.
MATERIALS AND METHODS
We retrospectively identified, using computerized
clinical and pathological databases, adult (> 18 years of
age) patients with MDS who had undergone a kidney
biopsy in nephrology centers in nine university and
general hospitals in France and Switzerland. Patients’
records were reviewed and relevant clinical and bio-
logical data were extracted. Kidney biopsies were
locally reviewed in each pathology centre by an expert
kidney pathologist. Glomerular filtration rate (eGFR)
(ml/min/1.73m2) was estimated using the CKD-EPI
equation.12 Nephrotic syndrome was defined by a
proteinuria > 3 g/day and a serum albumin < 30 g/l.
This study was approved by the local research ethics
committee (Swissethics, CER-VD, project number 2020-
00167). Data are presented as percentages or medians
and ranges.
We also performed a search using PubMed, with the
following keywords: myelodysplasic syndromes, kid-
ney biopsy, glomerulonephritis, interstitial nephritis,
in order to identify previously reported cases of ne-
phropathies documented by kidney biopsy in MDS
patients.
RESULTS
Nineteen patients (5 female, 14 male; median age 74
years [63-83 years]) with MDS who had undergone a
kidney biopsy between 2001 and 2019 were included.
In the three centres that included the highest number
of patients, kidney biopsy was performed in less thanKidney International Reports (2021) 6, 746–7541% of MDS patients followed in each institution dur-
ing the inclusion period. Patients’ characteristics are
shown in Table 1 and Table 2. Median time between
MDS diagnosis and kidney biopsy was 1.5 years [0-7].
The diagnosis of MDS preceded the onset of kidney
disease in 13 cases and was made concomitantly to or
less than two months after kidney biopsy in six cases.
At time of kidney biopsy, 11 (58%) patients had extra-
renal manifestations. Median serum creatinine at diag-
nosis was 2.8 mg/dl [0.6-8.3] and all patients except
three (patients 13, 18 and 19) presented with acute
kidney injury. Patients 3 and 7 had a pre-existing
chronic kidney disease of unknown cause with an
eGFR of 40 and 34 ml/min/1.73 m2, respectively. Me-
dian urinary protein to creatinine ratio was 1.2 g/g [0.2-
11] and two patients had a nephrotic syndrome.
Microscopic haematuria was present in fifteen patients
(macroscopic haematuria in patient 10). Anti-nuclear
factors were detected in patients 5, 10, 11 and 17,
anti-DNA antibodies and anti-cardiolipin antibodies
(IgM) in patient 10 and anti-myeloperoxidase ANCA in
patient 17.
Detailed pathology findings in kidney biopsies are
shown in Table 3. The most frequent feature in kidney
biopsies was acute tubulo-interstitial nephritis (TIN)
present in seven (37%) patients (superimposed on
chronic TIN in one patient) (Figure 1a-e). One addi-
tional patient had acute TIN associated to a glomeru-
lonephritis. None of the patients with TIN had a new
medication (particularly antibiotics and non-steroidal
anti-inflammatory drugs) introduced in the last 6
months preceding acute kidney injury or kidney bi-
opsy, except for patient 5 who received corticosteroids
for arthritis two months earlier. Two patients (patients
2 and 3) only were on long-term treatment with a
proton-pump inhibitor (detailed list of long-term
treatment in patients with TIN is shown in Table S1).
Patient 4 was on azacitidin at the time of acute kidney
injury but was maintained on long-term azacitidin
without any recurrence of acute TIN after corticoste-
roids withdrawal. Immunofluorescence study in pa-
tient 5 with acute TIN disclosed intense deposits of
polyclonal IgG along the tubular basement membrane
and Bowman’s capsule. The intensity of staining was
similar for the IgG1, 2, 3 and 4 subclasses (Figure 1d).
Other pathological features included ANCA-negative
pauci-immune necrotizing and crescentic glomerulo-
nephritis (n ¼ 3), membranous nephropathy (n ¼ 2)
(Figure 1f and g), IgA nephropathy (n ¼ 1), IgA
vasculitis (n ¼ 1), immunoglobulin-associated mem-
brano-proliferative glomerulonephritis type I (n ¼ 1)
(Figure 1h and i), crescentic C3 glomerulopathy (n ¼ 1),
fibrillary glomerulonephritis (n ¼ 1) and minimal
change disease (n ¼ 1). In one patient, kidney biopsy747
Table 1. Characteristic of 19 patients with myelodysplastic syndromes (MDS) who had undergone a kidney biopsy
Pt
Gender
Age (y) MDS type Treatment at KB
Time between MDS
and KB (y)
At time of KB







1 M, 74 MDS-MLD EPO 3 6.2 Anuria þþþ 229 Fever, livedo, scleritis,
polychondritis, coeliac disease
Acute TIN Cs CKD: SCr 1.6-1.8 mg/dl (eGFR
36 ml/min/1.73 m2) at 1 year.
2 M, 76 MDS-RS EPO, 2 3.2 0.3 g/l - 29 - Acute TIN Cs SCr 1 mg/dl (eGFR 74 ml/min/1.73m2)
and U P/Cr < 0.5 g/g at 5 months.
3 M, 74 MDS with
isolated del(5q)
EPO > 1 y 2.9* 0.47 þ 17 Polychondritis Acute TIN - ESKD at 1 month.
4 F, 76 MDS-EB Azacitidin 1.5 4.5 0.6 þþþ 115 Fever, arthralgia, buccal
ulcerations, skin nodules
Acute TIN - CKD: SCr 2.5 mg/dl (eGFR
18 ml/min/1.73m2) at 3 years
5 M, 83 NA - Concomitant 1.9 0.8 g/l - 13 Arthralgia Acute TIN Cs CKD: SCr 1.4 mg/dl (eGFR
46 ml/min/1.73m2) at 3 months.
6 M, 80 MDS-MLD EPO 1.6 3.6 1.5 þþ 50 - Acute TIN
IgAN
- ESKD (patient declined dialysis)
and Death 1 year later (AML).
7 M, 79 Not available EPO, deferoxamin 7 8.3* 0.6 þþþ 142 - Subacute TIN. None ESKD at 1 month
8 F, 69 MDS-EB RBC transfusions 1.5 3.7 3.9** þþþ 50 Neutrophilic urticaria, sicca
syndrome
ANCA-negative PiNCG CsþMMF /
AZA
ESKD at 6 months.




4 1.1 þþþ 319 Fever, pleuritis ANCA-negative PiNCG CsþCYPa
RTX
CKD: SCr 2.4 mg/dl (eGFR
25 ml/min/1.73m2) at 6 years.
10 M, 73 MDS-MLD EPO, GM-CSF 7 5.1/HD 2.3g/l þþþM 76 Thrombocytopenia ANCA-negative PiNCG CsþRTX SCr decreased to 2 mg/dl at 3 weeks but
increased again following septic
shock and HD was restarted.





Partial remission of the NS at 8 months
(Alb, 38 g/l, Puria 1.4 g/24h). Stable CKD:
SCr 1.25 mg/dl (eGFR 51 ml/min/1.73m2).
12 F, 72 MDS-MLD EPO, RBC transfusions 1 1.3 7.9£ - 5 - MN ACEI Stable CKD: SCr 1.5 mg/dl (eGFR 35 ml/min/1.73m2)
and Puria 2 g/day at 15 months.
13 F, 78 MDS-SLD EPO > 3 1 0.8 þþþ 35 Purpura (leukocytoclasic vasculitis) IgA vasculitis - Stable CKD (SCr 0.9 mg/dl; eGFR 58 ml/min/1.73m2)
and proteinuria (< 1g/24h) at 8 years
14 M, 69 MDS-MLD - Concomitant 1.4 1 þþþ - IgAN None Stable CKD: SCr 1.4 mg/dl (eGFR
50 ml/min/1.73m2) at 2 years.
15 M, 63 MDS-U Azacitidin 1 1.6 1 g/l þþ < 5 - Ig-MPGN type 1 None Stable CKD: SCr 2 mg/dl (eGFR 33 ml/min/1.73 m2).
Death 6 years later (AML)




ESKD at 3 months.
17 F, 75 MDS-MLD EPO 1 month 4.5 11 þþþ 32 - Fibrillary GN Cs, RTX CKD: SCr 2.7 mg/dl (eGFR 24 ml/min/1.73m2) at 3
months.
18 M, 80 MDS-RS RBC transfusion 2 0.6 9.7 g/l - < 5 - MCD Cs Partial remission of NS. Death 1 month later (septic
shock).
19 M, 80 MDS-U RBC transfusions, EPO, GM-
CSF, deferoxamin
4 0.6 1.24 þþþ 123 Peripheral neuropathy Normal Cs Stable normal SCr.
Normalization of proteinuria (0.3 g/24h)
ACEI, angiotensin converting enzyme inhibitor; AML, acute myeloid leukemia; ANCA, anti-neutrophil cytoplasm antibodies; AZA, azathioprine; Cs, corticosteroids; CKD, chronic kidney disease; CRP, C-reactive protein; CYP, cyclophosphamide; EB,
excess of blasts; Ecu, eculizumab; eGFR, estimated glomerular filtration rate;.EPO, erythropoietin; ESKD, end-stage kidney disease; F, female; GM-CSF, Granulocyte Macrophage Colony-Stimulating Factor; H, hematuria; HD, haemodialysis; IgAN, IgA
nephropathy; IgG GN, IgG glomerulonephritis; Ig-MPGN, immunolglobulin-mediated membrano-proliferative glomerulonephritis; KB, kidney biopsy; M, male; MCD, minimal change disease; MLD, multiple lineage dysplasia; MMF, mycophenolate
mofetil; MN, membranous nephropathy; NS, nephrotic syndrome; PiNCG, pauci-immune necrotizing and crescentic glomerulonephritis; Pt, patient; RBC, red blood cells; RS, ring sideroblasts; RTX, rituximab; SCr, serum creatinine; SLD, single lineage
dysplasia; TIN, tubulo-interstitial nephritis; TRT, treatment; U, unclassifiable; U P/Cr, urinary protein to creatinine ratio; Y, years.
*patient with pre-existing CKD
**NS, serum albumin 27 g/l
***NS, serum albumin 25 g/l
£, absence of NS, serum albumin 42 g/l
aThe patient developed pancytopenia within two weeks of the start of cyclophosphamide (single infusion) and was switched to rituximab

























































































Table 2. Characteristics of 19 patients with myelodysplastic syndromes (MDS) and nephropathies documented by kidney biopsy, including
seven patients with tubule-interstitial nephritis and twelve with glomerulopathies. Values are medians (range) or percentages
Characteristics Tubulo-interstitial nephritis (n [ 7) Glomerulopathy (n [ 12) All (n [ 19)
Age (years) 76 (74-83) 73.5 (63-80) 74 (63-83)
Female 1 (14%) 4 (33.3%) 5 (26%)
Chemotherapy at the time of kidney biopsy 2 (29%) 1 (8.3%) 3 (16%)
Time between MDS and kidney biopsy (years) 1.6 (0-7) 1 (0-7) 1.5 (0-7)
Serum creatinine (mg/dl) 3.6 (1.9-8.3) 2.1 (0.6-5.1) 2.75 (0.6-8.3)
Urinary Protein/Creatinine (g/g) 1.05 (0.6-4.7) 1.2 (0.2-11) 1.2 (0.2-11)
Haematuria 5 (71%) 10 (83%) 15 (79%)
Extra-renal manifestations 4 (57%) 7 (58%) 11 (58%)
Treatment
Immunosuppression 3 (43%) 8 (67%) 11 (58%)
Supportive care 4 (57%) 4 (33%) 8 (42%)
Outcome
Remission 1 (14%) 1 (8%) 2 (11%)
Chronic kidney disease 3 (43%) 6 (50%) 9 (47%)
Dialysis 2 (29%) 3 (25%) 5 (26%)
Death 1 (14%) 2 (17%) 3 (16%)
N Schwotzer et al.: Myelodysplastic Syndromes and the Kidney CLINICAL RESEARCHwas normal and the diagnosis of polyarteritis nodosa
was made based on the presence of distal arterial micro-
aneurysms on renal arteriography.
Among the two patients with membranous ne-
phropathy, patient 11 had persistently negative anti-
phospholipase A2 receptor 1 (PLA2R1) antibodies but
a positive PLA2R1 staining in his second kidney bi-
opsy. The status of anti-PLA2R1 antibodies is un-
known for patient 12. The two patients with C3
glomerulopathy and immunoglobulin-associated mem-
brano-proliferative glomerulonephritis type I had
normal C3 and C4 plasma levels and patient 16 had no
detectable C3 nephritic factor, anti-factor H and anti-
factor B antibodies.
Three patients had a repeat biopsy that confirmed
the diagnosis based on the first biopsy in patient 11 and
the resolution of acute kidney lesions following treat-
ment in patients 4 and 9.
Eleven (58%) patients received immunosuppressive
treatments, including steroids in all. In patient 9, se-
vere pancytopenia occurred within two weeks after the
start of cyclophosphamide and the diagnosis of MDS
was made (the patient was subsequently switched to
rituximab). One patient had severe infectious compli-
cations (pneumonia) related to immunosuppressive
treatments. After a median follow-up of 7 months [1-
96], nine (47%) patients had CKD stage 3 (n ¼ 6) or 4
(n ¼ 3) and five (26%) had progressed to end-stage
kidney disease. Three patients died in the setting of
acute myeloid leukemia and septic choc.
The search in the literature retrieved only six cases
of kidney biopsies performed in adult patients with
MDS (Table 4). Median age at kidney biopsy was 64
years [61-74 years]. Kidney biopsies disclosed a mem-
branous glomerulonephritis (MN) in four cases, anKidney International Reports (2021) 6, 746–754ANCA-associated pauci-immune necrotizing and cres-
centic glomerulonephritis in one, and an
immunoglobulin-associated membrano-proliferative
glomerulonephritis in one. In five cases, MDS was
diagnosed in the workup of the newly diagnosed ne-
phropathy and in one case, MDS was diagnosed 6
month after kidney biopsy. During follow-up, one
progressed to end-stage kidney disease.DISCUSSION
The present study is the first description of the spec-
trum of kidney diseases documented by kidney biopsy
in patients with MDS. It clearly indicates that the
kidney, along with other organs, is a target of auto-
immunity in the setting of MDS. The predominant
pathological feature in our series was acute TIN present
in 37% of cases. Thus, MDS are, most probably, to be
listed among the disorders associated to acute TIN. The
absence of previous published series has potentially led
to the under-recognition (and hence to the under-
diagnosis) of the association of acute TIN with MDS.
Acute TIN has been reported in patients with chronic
myelomonocytic leukemia,13 a hemopathy which was
previously included in the spectrum of MDS. However,
TIN in chronic myelomonocytic leukemia patients is
either due to lysozyme toxicity14 or to a specific
leukemic infiltrate, in contrast to the non-specific
infiltrate composed mostly of lymphocytes and mac-
rophages seen in MDS patients. Finally, no case of TIN
associated with MPN has been documented in pub-
lished series.15,16
Based on our findings, the diagnostic workup of an
acute TIN should include an assessment for the pres-
ence of MDS and both disorders can be concomitantly749




Vessels IF DiagnosisGlomeruli Tubules Interstitium
1 9 (4 sclerotic).
Normal appearance.
Rare atrophic tubules Edema and diffuse (þþ) inflammatory cells infiltrate
(mononuclear cells)
Normal Mesangial IgA deposits (þ/þþ) Acute TIN
2 22 (1 sclerotic)
Normal appearance.
Epithelial cell vacuolization.
Exocytosis of inflammatory cells in
tubular sections
Oedema and diffuse (þþþ) inflammatory cells infiltrate
(lymphocytes and plasmocytes). Fibrosis < 10%
Mild arteriosclerosis No significant deposits. Acute TIN
3 20 (9 sclerotic). Focal segmental lesions. Absence of proliferation. Several tubular atrophy
Focal tubulitis
Inflammatory cell infiltrate (þþ/þþþ) (lymphocytes,









Acute tubular necrosis Oedema and inflammatory cells infiltrate (þþ/þþþ)




No glomeruli. Acute TIN
2nd KB (4 months later)
12 glomeruli (3 sclerotic). Normal appearance.





5 13 glomeruli (3 sclerotic).
Absence of proliferation.
Thickening of Bowman’s capsule (5 glomeruli).
Deposits within the tubular
basement membrane
Acute injury in rare tubules





Polyclonal IgG (þþ/þþþ) deposits in
Bowman’s capsule and TBM.
Similar staining for IgG 1-4 subclasses.
Acute TIN
6 13 /2 (sclerotic).
Mild mesangial proliferation (þ).
Focal segment lesions (2 glomeruli).
Focal tubular atrophy Inflammatory cell infiltrate (þþ) (lymphocytes/
plasmocytes) in 30% of the cortical area. Fibrosis 60%
Mild intimal fibrosis Mesangial IgA and C3 deposits (þþ). Acute TIN.
IgAN
7 8 (2 sclerotic).
Normal appearance.
Mild tubular atrophy Focal (þ/þþ) inflammatory cell infiltrate (lymphocytes).
Fibrosis 30-40%
Mild intimal fibrosis No significant deposits. Subacute/
Chronic
TIN
8 17 (0 sclerotic).
Fibrinoid necrosis (3 glomeruli).
Cellular or fibrocellular crescents (3 glomeruli).
Tubular atrophy Giant-cell granulomas
Fibrosis 50%
Normal No significant deposits PiNCG
9 1st KB
12 (2 sclerotic). Fibrinoid necrosis (2 glomeruli). Glomerular
infiltration by neutrophils.
Rare atrophic tubules Cortical inflammatory cell infiltrate (þ/þþ) (neutrophils,
lymphocytes, plasmocytes)
Fibrosis 20%
Mild intimal fibrosis No significant deposits. PiNCG
2nd KB (10 months later). 10 glomeruli (2 sclerotic). Normal
appearance.
Mild (þ/þþ) tubular atrophy Fibrosis 30-40% Normal No significant deposits.
10 11 (1 slerotic).
Cellular crescents (3 glomeruli).
Intra-glomerular inflammatory cells.
Segmental aspects of TMA.




No significant deposits. PiNCG
11 1st KB
22 (1 sclerotic). Stiffness of the capillary walls. Absence of
proliferation.
Normal Normal Mild intimal fibrosis Granular IgG (þþþ), C3 (þþþ) and IgM
(þ) along the capillary walls. Negative
PLA2R1 staining.
MN
2nd KB (6 months later).
19 (1 sclerotic). Thickening of the capillary walls. Presence of
inflammatory cells (lymphocytes, monocytes, neutrophils) in
capillaries.
Mild atrophy Mild to severe fibrosis
Moderate (þ/þþ) inflammatory cell infiltrate (lymphocytes)
Mild intimal fibrosis Granular IgG (þþþ), C3 (þþþ) along the
capillary walls.
Positive PLA2R1staining.
12 10 (0 sclerotic).
Deposits and spikes along the basement membrane.
Mild tubular atrophy Mild fibrosis Mild arteriosclerosis Parietal granular polyclonal IgG (þþþ)
deposits.
MN
13 9 glomeruli (0 sclerotic). Mild mesangial proliferation (þ/þþ). Normal Fibrosis < 20% Mild arteriosclerosis Mesangial and parietal IgA (þþ), fibrin (þþ)
and C3 (þ) deposits.
IgA
vasculitis
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Kidney International Reports (2021) 6, 746–754diagnosed, as exemplified by one case from this series.
The presence of an intense staining of the tubular
basement membrane (and of Bowman’s capsule) with
polyclonal IgG in one patient reported here is highly
intriguing. It suggests that a humoral autoimmune
process (along with a cellular one) may be involved in
the pathogenesis of TIN in the setting of MDS. Sera
from MDS patients with TIN in this series were not
available for the detection of potential circulating au-
toantibodies targeting the tubular sections. However,
anti-tubular basement membrane antibodies have been
previously reported in patients with acute TIN17 and
are believed to be directed against a 58-kDa non-
collagenous protein involved in the regulation of
tubulogenesis.
The other kidney pathological findings in MDS pa-
tients from this series encompass a wide range of
autoimmune glomerulonephritis. Some of these ne-
phropathies have been previously reported in MDS
patients in a limited number of case reports, particu-
larly membranous nephropathy (Table 4). However our
findings are remarkable for the presence of very rare
glomerulopathies: ANCA-negative pauci-immune
necrotizing and crescentic glomerulonephritis,18 cres-
centic C3 glomerulopathy,19 fibrillary glomerulone-
phritis20,21 and immunoglobulin-associated
membranoproliferative glomerulonephritis. The occur-
rence of these glomerulopathies may result from a
MDS-linked autoimmune dysregulation (including
complement dysregulation) and abnormal activation of
granulocytes in ANCA-negative necrotizing and cres-
centic glomerulonephritis. Interestingly, ANCA nega-
tive7 and more rarely ANCA positive10 as well as IgA22
extra-renal vasculitis have been reported in MDS pa-
tients. Besides, C3 glomerulopathy and
immunoglobulin-associated membranoproliferative
glomerulonephritis have been linked to autoimmune
processes.23 Furthermore, fibrillary glomerulonephritis
probably results from glomerular deposition of immune
complexes that have the ability to undergo fibrilo-
genesis21 and has been reported in the setting of
various auto-immune diseases, including systemic
lupus erythematous and Sjögren’s syndrome.20 How-
ever, the exact mechanisms underlying autoimmune
manifestations in MDS patients remain speculative.24
The rarity of these autoimmune glomerulonephritis
(and the relative rarity of acute unexplained TIN) is the
first argument against a fortuitous association between
MDS and nephropathies described herein. Further-
more, as already stated, autoimmunity is a well-
recognized feature of MDS in extra-renal organs. Half
of the patients included in this series had extra-renal
manifestations at the time of kidney biopsy and 20%








Figure 1. (a-d) Patient 5 (Table 1). A 83-year old male patient with MDS was admitted for acute kidney injury. A kidney biopsy was performed.
Light microscopy study: A (Masson’s trichrome staining, x200), B (Masson’s trichrome staining, x400) and C (Jones staining, x600). An interstitial
inflammatory cell infiltrate was present (A, *) and a thickening of the tubular basement membranes and of Bowman’s capsules with the
presence of deposits was noted (A-C, #). The immunofluorescence study (D, x200) disclosed intense IgG staining of the tubular basement
membranes and Bowman’s capsules. (e) Patient 4 (Table 1). A 76-year old female patient with MDS was admitted for severe acute kidney injury
associated with extra-renal symptoms (fever, arthralgia, buccal ulcerations, skin nodules) A kidney biopsy was performed. Light microscopy
study, Masson’s trichrome staining, x200. An interstitial inflammatory cell infiltrate was present (*) and inflammatory cells were also noted in the
lumen of peritubular capillaries (#). (f-g) Patient 11 (Table 1). A 74-year male patient with MDS was admitted for an acute kidney injury and a
nephrotic syndrome. A kidney biopsy was performed. Light microscopy study, (F, Jones staining, x400). Minor alterations of the glomerular
capillary walls (*) were noted in the absence of any proliferation. Inflammatory cells were present in the lumen of the glomerular capillaries (#).
Immunofluorescence study (G, x 400) disclosed the presence of parietal subepithelial IgG deposits. (h-i) Patient 15 (Table 1). A 63-year male
patient with MDS was admitted for acute kidney injury and mild proteinuria. Light microscopy examination revealed mild mesangial expansion
and on immunofluorescence study (H, x400) mesangial and parietal IgG deposits were present (along with C3 deposits). Electron microscopy
study (I, x8900) disclosed non-electron dense deposits (*) within the basement membrane.
CLINICAL RESEARCH N Schwotzer et al.: Myelodysplastic Syndromes and the Kidneynecessarily pathogenic.24 Besides, in six out of 19 pa-
tients, the diagnosis of MDS was made concomitantly
or shortly (less than 2 months) after kidney biopsy and
acute kidney injury. Nevertheless, the nature of the
glomerulopathies associated to MDS in the present
study was heterogeneous and a definite link between
these glomerular diseases and the underlying hemop-
athy cannot be formally established. However, extra-
renal auto-immune manifestations, frequently re-
ported in MDS patients, are similarly highly hetero-
geneous in their presentation and severity.4
Noteworthy, the glomerular pathological findings in
our patients with MDS sharply contrast with those752previously documented in MPN, particularly the
“MPN-related glomerulopathy” characterized by
mesangial sclerosis and hypercellularity, segmental
sclerosis, features of chronic thrombotic micro-
angiopathy, and intracapillary hematopoietic cell
infiltration.16
The treatment of nephropathies associated with MDS
relies mostly on immunosuppressive treatments, which
carry specific morbidity (mostly infectious) and mor-
tality, as illustrated by several cases from the present
series. Moreover, the use of cytotoxic drugs may lead
to a worsening of MDS-associated cytopenias or un-

















































































































































































































































































































































































































































































































































































































































































































































N Schwotzer et al.: Myelodysplastic Syndromes and the Kidney CLINICAL RESEARCH
Kidney International Reports (2021) 6, 746–754series. Rapid tapering of steroids and, when feasible,
the use of non-cytotoxic agents (such as rituximab) is
recommended in these patients.
In total, the kidney is a new identified target of
autoimmunity in MDS patients. MDS are associated to
several autoimmune kidney manifestations, predomi-
nantly acute TIN, and more rarely various immune
glomerulonephritis.DISCLOSURE
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